83 citations
,
April 1992 in “Clinical Endocrinology” This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.
64 citations
,
January 1985 in “Clinical endocrinology” In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.
20 citations
,
July 1990 in “Clinical and experimental dermatology” In this study, women treated for androgen-dependent alopecia with CPA EE2 therapy experienced significant decreases in serum vitamin B12, hemoglobin, and hematocrit levels after six months.
14 citations
,
January 1980 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.
11 citations
,
April 2017 in “The European Journal of Contraception & Reproductive Health Care” This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.
9 citations
,
December 1987 in “European journal of endocrinology” In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.
8 citations
,
November 1978 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, cyproterone acetate was found to be effective in treating 'idiopathic' hirsutism, while a combination of ethinyloestradiol and lynoestrenol reduced hair growth in fewer patients despite uniformly lowering testosterone levels.
8 citations
,
April 1990 in “Hormone and Metabolic Research” This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.
35 citations
,
July 2008 in “International Journal of Gynecology & Obstetrics” This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.
20 citations
,
November 2015 in “International Journal of Gynecology & Obstetrics” Among women with polycystic ovary syndrome, this study found that oral contraceptives containing 20 μg ethinyl estradiol had similar effects on androgen levels as those containing 30 μg.
18 citations
,
March 2010 in “Gynecologic and obstetric investigation” This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.
This study observed that women using combined oral contraceptives experienced more nausea, vomiting, and hair loss, while those on Depo-Provera were more likely to gain weight.
May 2020 in “International Journal of Clinical Obstetrics and Gynaecology” This article reviews the medical history and symptoms related to hyperandrogenism in patients, but reports no new clinical findings.
February 2020 in “İstanbul medical journal” This study evaluated the effects of metformin, ethinyl estradiol/cyproterone acetate (EE/SA), and their combination on carotid intima-media thickness and various cardiovascular markers in patients with polycystic ovary syndrome.
53 citations
,
January 1985 in “Acta obstetricia et gynecologica Scandinavica” This study found that an 8-month treatment with a low-dose oral contraceptive significantly reduced testosterone levels and hair growth in women with polycystic ovary syndrome and hirsutism, with minimal side effects.
52 citations
,
April 2008 in “Therapeutics and clinical risk management” This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.
42 citations
,
December 1976 in “PubMed” This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.
12 citations
,
August 2017 in “Pharmaceutical medicine” This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.
11 citations
,
October 1986 in “International Journal of Gynecology & Obstetrics” This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.
6 citations
,
October 2016 in “Contraception” This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.
6 citations
,
March 2012 in “Journal of the European Academy of Dermatology and Venereology” This study found that 12 cycles of chlormadinone acetate in hormonal contraceptives significantly improved oily skin and hair quality, enhancing psychosocial well-being in healthy women.
5 citations
,
July 2020 in “PubMed” This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.
5 citations
,
July 1987 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.
3 citations
,
April 2017 in “Clinical Drug Investigation” The researchers concluded that after the 2013 EMA recommendation, there was an overall reduction in CPA/EE prescriptions, but no substantial change in patient diagnoses or potential concurrent hormonal contraceptive use.
1 citations
,
March 2013 in “The European Journal of Contraception & Reproductive Health Care” This publication discusses the political rationale behind the French regulator ANSM's decision to withdraw Diane®-35 from the market, in response to health concerns associated with third-generation oral contraceptives.
1 citations
,
January 2004 in “Drugs” Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.
January 2025 in “American Journal of Translational Research” This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.